Stephanie J Sohl1,2, Gurjeet S Birdee1, Sheila H Ridner3, Amy Wheeler4, Sandra Gilbert1, Danielle Tarantola5, Jordan Berlin1, Russell L Rothman1. 1. 1. Vanderbilt University School of Medicine, Nashville, TN. 2. 2. Wake Forest University, School of Medicine, Department of Social Sciences & Health Policy, Winston-Salem, NC. 3. 3. Vanderbilt University School of Nursing, Nashville, TN. 4. 4. California State University, Department of Kinesiology, San Bernardino, CA. 5. 5. Healing Yoga Foundation, San Francisco, CA.
Abstract
OBJECTIVE: Fatigue and other treatment-related symptoms are critical therapeutic targets for improving quality of life in patients with colorectal cancer during chemotherapy. Yoga is a promising intervention for improving these therapeutic targets and has been primarily investigated in the group-class format, which is less feasible for cancer patients with high symptom burden to attend. Thus, we developed a protocol for implementing yoga individually in the clinic among patients receiving chemotherapy. METHODS: We followed recommended domains for developing a yoga protocol to be used in an efficacy trial. These recommendations include consideration to the style, delivery, components of the intervention, dose, specific class sequences, facilitation of home practice, measurement of intervention fidelity, selection of instructors, and dealing with modifications. The intervention protocol was developed by an interdisciplinary team. PROTOCOL: Yoga Skills Training (YST) consists of four 30-minute in-person sessions and was implemented while in the chair during chemotherapy infusions for colorectal cancer with recommended daily home practice for eight weeks. Therapeutic goals of the YST are to reduce fatigue, circadian disruption, and psychological distress. Elements of the YST are awareness meditation, gentle seated movement, breathing practice, and relaxation meditation. Attention, comfort, and ease are also highlighted. CONCLUSION: This description of a protocol for integrating yoga with conventional cancer treatment will inform future study designs and clinical practice. The design of the YST is novel because it implements yoga-most commonly studied when taught to groups outside of the clinical setting- individually during clinical care.
OBJECTIVE:Fatigue and other treatment-related symptoms are critical therapeutic targets for improving quality of life in patients with colorectal cancer during chemotherapy. Yoga is a promising intervention for improving these therapeutic targets and has been primarily investigated in the group-class format, which is less feasible for cancerpatients with high symptom burden to attend. Thus, we developed a protocol for implementing yoga individually in the clinic among patients receiving chemotherapy. METHODS: We followed recommended domains for developing a yoga protocol to be used in an efficacy trial. These recommendations include consideration to the style, delivery, components of the intervention, dose, specific class sequences, facilitation of home practice, measurement of intervention fidelity, selection of instructors, and dealing with modifications. The intervention protocol was developed by an interdisciplinary team. PROTOCOL: Yoga Skills Training (YST) consists of four 30-minute in-person sessions and was implemented while in the chair during chemotherapy infusions for colorectal cancer with recommended daily home practice for eight weeks. Therapeutic goals of the YST are to reduce fatigue, circadian disruption, and psychological distress. Elements of the YST are awareness meditation, gentle seated movement, breathing practice, and relaxation meditation. Attention, comfort, and ease are also highlighted. CONCLUSION: This description of a protocol for integrating yoga with conventional cancer treatment will inform future study designs and clinical practice. The design of the YST is novel because it implements yoga-most commonly studied when taught to groups outside of the clinical setting- individually during clinical care.
Authors: Shiraz I Mishra; Roberta W Scherer; Claire Snyder; Paula M Geigle; Debra R Berlanstein; Ozlem Topaloglu Journal: Cochrane Database Syst Rev Date: 2012-08-15
Authors: M Carayol; P Bernard; J Boiché; F Riou; B Mercier; F Cousson-Gélie; A J Romain; C Delpierre; G Ninot Journal: Ann Oncol Date: 2012-10-05 Impact factor: 32.976
Authors: Alyson B Moadel; Chirag Shah; Judith Wylie-Rosett; Melanie S Harris; Sapana R Patel; Charles B Hall; Joseph A Sparano Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: Janice K Kiecolt-Glaser; Lisa Christian; Heather Preston; Carrie R Houts; William B Malarkey; Charles F Emery; Ronald Glaser Journal: Psychosom Med Date: 2010-01-11 Impact factor: 4.312
Authors: N M Gray; S J Hall; S Browne; U Macleod; E Mitchell; A J Lee; M Johnston; S Wyke; L Samuel; D Weller; N C Campbell Journal: Br J Cancer Date: 2011-05-10 Impact factor: 7.640